| IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response FJ Núñez, FM Mendez, P Kadiyala, MS Alghamri, MG Savelieff, ... Science translational medicine 11 (479), eaaq1427, 2019 | 210 | 2019 |
| Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice P Kadiyala, SV Carney, JC Gauss, MB Garcia-Fabiani, S Haase, ... The Journal of clinical investigation 131 (4), 2021 | 84 | 2021 |
| Adenovirus entry from the apical surface of polarized epithelia is facilitated by the host innate immune response PLN Kotha, P Sharma, AO Kolawole, R Yan, MS Alghamri, TL Brockman, ... PLoS pathogens 11 (3), e1004696, 2015 | 75 | 2015 |
| Current state and future prospects of immunotherapy for glioma N Kamran, MS Alghamri, FJ Nunez, D Shah, AS Asad, M Candolfi, ... Immunotherapy 10 (4), 317-339, 2018 | 69 | 2018 |
| Current approaches for glioma gene therapy and virotherapy K Banerjee, FJ Núñez, S Haase, BL McClellan, SM Faisal, SV Carney, ... Frontiers in Molecular Neuroscience 14, 621831, 2021 | 68 | 2021 |
| Enhanced angiotensin II-induced cardiac and aortic remodeling in ACE2 knockout mice MS Alghamri, NM Weir, MP Anstadt, KM Elased, SB Gurley, M Morris Journal of cardiovascular pharmacology and therapeutics 18 (2), 138-151, 2013 | 67 | 2013 |
| G-CSF secreted by mutant IDH1 glioma stem cells abolishes myeloid cell immunosuppression and enhances the efficacy of immunotherapy MS Alghamri, BL McClellan, RP Avvari, R Thalla, S Carney, CS Hartlage, ... Science Advances 7 (40), eabh3243, 2021 | 54 | 2021 |
| Targeting neuroinflammation in brain cancer: uncovering mechanisms, pharmacological targets, and neuropharmaceutical developments MS Alghamri, BL McClellan, CS Hartlage, S Haase, SM Faisal, R Thalla, ... Frontiers in pharmacology 12, 680021, 2021 | 47 | 2021 |
| Systemic delivery of an adjuvant CXCR4–CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy MS Alghamri, K Banerjee, AA Mujeeb, A Mauser, A Taher, R Thalla, ... ACS nano 16 (6), 8729-8750, 2022 | 45 | 2022 |
| Melanoma induced immunosuppression is mediated by hematopoietic dysregulation N Kamran, Y Li, M Sierra, MS Alghamri, P Kadiyala, HD Appelman, ... Oncoimmunology 7 (3), e1408750, 2018 | 41 | 2018 |
| H3. 3-G34 mutations impair DNA repair and promote cGAS/STING-mediated immune responses in pediatric high-grade glioma models S Haase, K Banerjee, AA Mujeeb, CS Hartlage, FM Núñez, FJ Núñez, ... The Journal of Clinical Investigation 132 (22), 2022 | 31 | 2022 |
| Novel role of aminopeptidase-A in angiotensin-(1–7) metabolism post myocardial infarction MS Alghamri, M Morris, JG Meszaros, KM Elased, N Grobe American Journal of Physiology-Heart and Circulatory Physiology 306 (7 …, 2014 | 24 | 2014 |
| Impact of epigenetic reprogramming on antitumor immune responses in glioma BL McClellan, S Haase, FJ Nunez, MS Alghamri, AA Dabaja, ... The Journal of clinical investigation 133 (2), 2023 | 22 | 2023 |
| T lymphocytes as dynamic regulators of glioma pathobiology EC Cordell, MS Alghamri, MG Castro, DH Gutmann Neuro-oncology 24 (10), 1647-1657, 2022 | 19 | 2022 |
| Tumor mutational burden predicts survival in patients with low-grade gliomas expressing mutated IDH1 MS Alghamri, R Thalla, RP Avvari, A Dabaja, A Taher, L Zhao, PJ Ulintz, ... Neuro-oncology Advances 2 (1), vdaa042, 2020 | 19 | 2020 |
| Prospects of biological and synthetic pharmacotherapies for glioblastoma DB Altshuler, P Kadiyala, FJ Nuñez, FM Nuñez, S Carney, MS Alghamri, ... Expert opinion on biological therapy 20 (3), 305-317, 2020 | 18 | 2020 |
| Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development MB Garcia-Fabiani, M Ventosa, A Comba, M Candolfi, AJ Nicola Candia, ... Expert Opinion on Investigational Drugs 29 (7), 659-684, 2020 | 17 | 2020 |
| A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1 D Shah, A Comba, SM Faisal, P Kadiyala, GJ Baker, MS Alghamri, ... Oncoimmunology 10 (1), 1939601, 2021 | 16 | 2021 |
| Genetic alterations in gliomas remodel the tumor immune microenvironment and impact immune-mediated therapies MB Garcia-Fabiani, S Haase, A Comba, S Carney, B McClellan, ... Frontiers in Oncology 11, 631037, 2021 | 13 | 2021 |
| Functional assay to assess T-cell inhibitory properties of myeloid derived suppressor cells (MDSCs) isolated from the tumor microenvironment of murine glioma models MS Alghamri, N Kamran, P Kadiyala, PR Lowenstein, MG Castro Methods in enzymology 632, 215-228, 2020 | 9 | 2020 |
